Physicians' Academy for Cardiovascular Education

Which patients to consider for GLP-1RA?

5 Things a cardiologist needs to know about GLP-1RA

*NEW* Click on video for subtitling in English, German, Italian, Spanish, French, or Chinese.

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Villingen-Schwenningen, Germany

Video navigation menu

  • Case presentation - Should we modify the glucose lowering medication? 00:23
  • What would the guidelines recommend? 02:19
  • Evolution of treatment recommendations in management of T2DM 04:22
  • Use of anti-glycemic drugs with CV benefit in reality 05:41
  • Who should modify the risk management - a Cardiometabolic specialist? 06:42

Transcript

Show transcript

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1 RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2D and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.

Faculty

Prof Stephan Jacob, MD - endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany.

Disclosures

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Or listen to the podcast of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: